Merck Serono and Flamel to Collaborate on an Extended Release Formulation for Therapeutic Proteins
News Dec 26, 2007
Merck Serono, a division of Merck KGaA, announced has that it has entered into a collaboration with Flamel Technologies to investigate the applicability of Flamel's Medusa® technology for the extended release of a therapeutic protein of Merck Serono's portfolio.
Under the terms of the agreement, Merck Serono will make an upfront payment of EUR 2 million to Flamel for investigating the therapeutic protein and Merck Serono will fund R&D efforts to be performed at Flamel. Financial terms of a license agreement up through potential commercialization of this formulation have been agreed between the parties.
"We are delighted to enter into this partnership with Flamel, as it gives Merck Serono access to a technology that may further improve the therapeutic potential of compounds in our portfolio", said Bernhard Kirschbaum, Merck Serono's Head of Research.
"As Flamel's Medusa® technology allows for longer intervals between administrations of injectable proteins compared to standard formulations, we hope to offer an improved convenience for patients requiring treatment by injection. As a consequence, we anticipate that employing this technology will lead to better treatment outcomes for patients."
Stephen H. Willard, Flamel's Chief Executive Officer, stated, "We are pleased to have reached an agreement with Merck Serono. The Medusa® platform is a best-in-class technology for the controlled delivery of proteins, peptides, and other molecules. This applicability to a wide range of molecules is a key strength of the platform, as is the ability to sustain release without affecting bioactivity. Merck Serono is the ideal partner for this project and we look forward to working together on such an exciting opportunity."
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE